|
KMID : 1137020210320020031
|
|
Journal of Gynecologic Oncology
2021 Volume.32 No. 2 p.31 ~ p.31
|
|
|
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
|
|
Lee Yong-Jae
Lim Myong-Cheol
Kim Byoung-Gie
Ngoi Natalie Y. L.
Choi Chel-Hun
Park Sang-Yoon
Tan David S. P.
Go Yun-Jung
Lee Jung-Yun
|
|
|
Abstract
|
|
|
Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.
Methods: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.
|
|
|
KEYWORD
|
|
|
Ovarian Neoplasms, Bevacizumab, Poly(ADP-ribose) Polymerase Inhibitors, Immunotherapy Recurrence
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|